Text Size

Country:Korea

Korea

RNL-Astrostem is administered by intravenous infusion so patients don’t have to worry about any invasive and painful surgical procedure. Dr. Jeong Chan Ra, CEO of the firm, said “Our stem cell therapeutics involves no immune rejection because the stem cells are exactly patients own. Our adult stem cell has no tumorigenicity activity at all while embryonic stem cell faces high risk o ...
Read More...

ManufacturerRNL Bio
Hits856
Updated12 May 2010